MétaCan
Menu
Retour à la cohorte
Enregistrement W4405040167 · doi:10.1182/blood-2024-210782

Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome

2024· article· en· W4405040167 sur OpenAlexaff
Austin Boucher, Wojciech Rosikiewicz, Ricky Tirtakusuma, Anitria Cotton, Madeline Niederkorn, Elvin Wagenblast, Paul G. Thomas, Yubin Ge, Jeffrey W. Taub, Jan‐Henning Klusmann, John D. Crispino

Notice bibliographique

RevueBlood · 2024
Typearticle
Langueen
DomaineMedicine
ThématiqueChronic Myeloid Leukemia Treatments
Établissements canadiensMount Sinai Hospital
Organismes subventionnairesnon disponible
Mots-clésMyeloid leukemiaCohesinCancer researchGeneticsMutationLeukemiaMedicineMyeloidBiologyGeneChromosome

Résumé

récupéré en direct d'OpenAlex

Children with Down syndrome (DS) are at a 150-fold risk of developing acute megakaryoblastic leukemia. Known as the myeloid leukemia of Down syndrome (ML-DS), this disease is characterized by defined progressive stages that make it an ideal model to study leukemic transformation. While trisomy 21 alters steady state hematopoiesis, the addition of a GATA1 mutation, detected in nearly 30% of children with DS, frequently promotes transient abnormal myelopoiesis (TAM), a self-limiting pre-leukemia. Although TAM typically resolves within the first few months of life, 10-20% of individuals with TAM acquire an additional mutation that transforms the disease into ML-DS. Among these secondary mutations, cohesin alterations are seen in more than 50% of cases, far more than the incidence of these mutations in the general population of AML patients. Cohesin is a ring-shaped protein complex consisting of proteins SMC1, SMC3, RAD21, and either STAG1 or STAG2. Recent reports have implicated the cohesin complex in numerous functions related to chromatin architecture regulating gene expression including but not limited to domain insulation, recruitment of transcription factors, and enhancer-promoter interactions. Due to the genome wide binding of cohesin, elucidating how its mutation leads to transformation has remained elusive. Leveraging the ML-DS patient derived cell line CMY which has a patient relevant RAD21 Y3* mutation, we generated two RAD21 mutant corrected isogenic clones by CRISPR/Cas9 editing. In vitro the corrected clones grow significantly slower than the parental line, and NSG mice injected with the corrected clones had improved overall survival. To investigate the mechanism by which cohesin contributes to transformation, we performed multi-omics studies, including RNA-seq, ATAC-seq, CUT&RUN, and HI-C. ATAC motif enrichment revealed that the clones had increased accessibility of CTCF motifs and decreased accessibility of GATA and RUNT motifs. CUT&RUN for GATA1s, RAD21 and CTCF showed a striking increase in differential occupancy upon correction. We then compared our RNA-seq results with those from a primary human fetal liver model of ML-DS. Strikingly, GSEA of the RNA-seq data revealed strong enrichment for antigen processing and presentation, underpinned by increased HLA class II gene expression in the corrected clones. Utilizing the pan HLA class II antibody HLA-DR,DP,DQ we found that the corrected clones had a 2.5 fold increased cell surface expression compared to parental CMY cells. These results mirror the decrease in HLA-DR expression in T21, GATA1 mutant human fetal liver cells upon the introduction of a STAG2 mutation. These results suggest that one action of cohesin mutations is to affect HLA Class II expression and raise the possibility that cohesin mutations promote immune response evasion. Next, we searched for cell intrinsic drivers of leukemia progression mediated by cohesin mutations. Gene sets enriched in the RNA-seq data included metabolic terms such as electron transport chain, mitochondria and lipids. To validate an effect on metabolism, we induced oxidative stress in the cells with hydrogen peroxide and subsequently measured mitochondrial ROS (mitoROS). Upon treatment, both corrected clones showed significantly less induction of mitoROS compared to the RAD21 mutant parental line. These results prompted us to perform unbiased metabolomics, which led to the identification of 45 significantly altered metabolites including serine, phosphoethanolamine, and CDP-choline that were enriched in the corrected clones. These three metabolites comprise a node of the Kennedy pathway that feeds into phospholipid metabolism. We then performed unbiased lipidomics where 159 significantly changed lipid species were identified. Lipid ontology analysis revealed significant enrichment of glycerophospholipids and fatty acids with >3 double bonds; 62 phospholipids (PLs) were enriched in CMY and 32 were enriched in corrected clones. Saturation levels were drastically different between the enriched PLs, where 46.8% were saturated in parental cells but only 12.5% in the corrected clones. Interestingly, GSEA of the CUT&RUN data revealed enrichment of adipogenesis and biosynthesis of unsaturated fatty acids pathways. Together, these results suggest a role for differential phospholipid metabolism in leukemia transformation in DS.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Expérimental (laboratoire) · Signal consensuel: Expérimental (laboratoire)
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,002
Score d'incertitude au seuil0,006

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0020,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,012
Tête enseignante GPT0,266
Écart entre enseignants0,254 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeExpérimental (laboratoire)
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2024
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBloodMême sujetChronic Myeloid Leukemia TreatmentsTravaux en français237 207